Viridian Therapeutics
viridiantherapeutics.com
Actively hiring
Health Care
Immunology & Inflammation Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$29M
2 rounds on record
Latest round
$27M
Venture round · Sep 2020 · 6 yr ago
Team
240
US Form 5500 (plan participants) · Dec 2025 · +64% in a year
Backers
2
Broadview Ventures, Longitude Capital
The money's age
Long since its last round
72 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2020 | $27M | — | SEC Form D |
| Venture round | Apr 2020 | $2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Viridian Therapeutics, Inc. | sec |
Founders and leadersfrom filings, registers and the company's site
Jonathan ViolinExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Broadview Ventures 
Longitude Capital Similar startupsby what they do, their industry and backers
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions.
Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune…
On a mission to transform the future of autoimmune care. Developing innovative therapies with the potential to redefine the standard of…
News
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.
Read more
Report
Report
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines ...
Read more
Report
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Read more
Report
Pro access
Upgrade to see all 8 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Jonathan Violin
Executive Officer, Director
Peter Harwin
Director
Tomas Kiselak
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Waltham
United States
HQ
Viridian Therapeutics, Inc.
Boulder
United States
Regional office
Colorado